36-Year-Old Severely Obese Male with Worsening Psoriasis
A morbidly obese 36-year-old male with moderate-to-severe psoriasis was refractory to adalimumab therapy. Obesity is thought to induce systemic inflammation that may augment psoriasis severity. Infliximab is the only commonly-utilized biologic for psoriasis that employs weight-based dosing, and its efficacy at a uniform dose has been demonstrated to be consistent across various body mass indices. After 2 months on infliximab coupled with weight loss on a new diet and exercise regimen, the patient’s affected body surface area decreased dramatically.
KeywordsObesity Inflammation Biologics Infliximab
- 11.Højgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford). 2016;55(12):2191–9. https://doi.org/10.1093/rheumatology/kew326.CrossRefGoogle Scholar
- 18.Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr. 2008;88(5):1242–7. https://doi.org/10.3945/ajcn.2008.26427.CrossRefPubMedGoogle Scholar
- 21.Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.CrossRefGoogle Scholar